# c-Kit

## SCFR; CD117

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

## c-Kit Inhibitors

### AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with $K_d$s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



**Purity:** 99.89%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib

**(MP470; HPK 56)**

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



**Purity:** 98.07%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Amuvatinib hydrochloride

**(MP470 hydrochloride; HPK 56 hydrochloride)**

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



**Purity:** >98%
**Clinical Data:** Phase 2
**Size:** 1 mg, 5 mg

### AST 487

**(NVP-AST 487)**

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with $IC_{50}$ of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with $IC_{50}$ of 520 nM.



**Purity:** 99.20%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### Avapritinib

**(BLU-285)**

Cat. No.: HY-101561

Avapritinib (BLU-285) is a highly potent, selective, and orally active **KIT** and **PDGFRA** activation loop mutant kinases inhibitor with $IC_{50}$s of 0.27 and 0.24 nM for **KIT D816V** and **PDGFRA D842V**, respectively.



**Purity:** 99.94%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with $IC_{50}$s of 8, 4, 7 and 9 nM in cell assay, respectively.



**Purity:** 96.11%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### AZD3229

Cat. No.: HY-112802

AZD3229 is a potent pan-**KIT** mutant inhibitor for the treatment of gastrointestinal stromal tumors.



**Purity:** 99.83%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### AZD3229 Tosylate

Cat. No.: HY-112802A

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.



**Purity:** 98.54%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### Bezuclastinib

**(CGT9486; PLX 9486)**

Cat. No.: HY-145557

Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of **c-kit** and **c-kit D816V** ($0.0001<IC_{50}<1$ μM; extracted from patent WO2014100620 A2, compound P-2007). Bezuclastinib is a tyrosine kinase inhibitor.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with $IC_{50}$s of <200 nM.



**Purity:** 98.72%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg


Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

## c-Kit-IN-2

Cat. No.: HY-128602

c-Kit-IN-2 is a **c-KIT** inhibitor with an $IC_{50}$ of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with $GI_{50}$s of 3, 1, and 2 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## c-Kit-IN-5-1

Cat. No.: HY-18302

c-Kit-IN-5 is potent inhibitor of **c-Kit**, with $IC_{50}$s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Cabozantinib

**(XL184; BMS-907351)**

Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with $IC_{50}$s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



**Purity:** 99.96%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Cabozantinib-d4

**(XL184-d4; BMS-907351-d4)**

Cat. No.: HY-13016S1

Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Cabozantinib-d6

Cat. No.: HY-13016S

Cabozantinib-d6 (XL184-d6) is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with $IC_{50}$s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



**Purity:** 98.14%
**Clinical Data:** No Development Reported
**Size:** 2.5 mg, 1 mg, 5 mg, 10 mg

## Chiauranib

**(CS2164)**

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



**Purity:** 99.28%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## CHMFL-ABL/KIT-155

**(CHMFL-ABL-KIT-155)**

Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor ($IC_{50}$s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK ($IC_{50}$=81 nM), CSF1R ($IC_{50}$=227 nM), DDR1 ($IC_{50}$=116 nM),...



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## CHMFL-KIT-033

Cat. No.: HY-128589

CHMFL-KIT-033 is a potent and selective inhibitor of **c-KIT T670I mutant** for gastrointestinal stromal tumors (GISTs), with an $IC_{50}$ of 0.045 μM.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Dovitinib

**(CHIR-258; TKI258)**

Cat. No.: HY-50905

Dovitinib (CHIR-258) is an orally active, potent **multi-targeted tyrosine kinase (RTK)** inhibitor with $IC_{50}$s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **CSF-1R**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



**Purity:** 99.94%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Dovitinib lactate

**(CHIR-258 lactate; TKI-258 lactate)**

Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with $IC_{50}$s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



**Purity:** 99.62%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Dovitinib lactate hydrate

**(TKI258 lactate hydrate; CHIR-258 lactate hydrate)** Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with $IC_{50}$s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Dovitinib-D8

Cat. No.: HY-50905S

Dovitinib-D8 (CHIR-258-D8) is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with $IC_{50}$s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Flumatinib

**(HHGV678)** Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with $IC_{50}$s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



**Purity:** 99.94%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Flumatinib mesylate

**(HHGV678 mesylate)** Cat. No.: HY-13905

Flumatinib mesylate (HHGV678 mesylate) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with $IC_{50}$s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



**Purity:** 99.97%
**Clinical Data:** Phase 4
**Size:** 10 mM × 1 mL, 500 mg

## Flumatinib-d3

**(HHGV678-d3)** Cat. No.: HY-13904S

Flumatinib-d3 is deuterium labeled Flumatinib. Flumatinib (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## IHMT-TRK-284

Cat. No.: HY-146697

IHMT-TRK-284 (Compound 34) is a potent, orally active **type II TRK kinase** inhibitor with $IC_{50}$ values of 10.5, 0.7, and 2.6 nM to **TRKA, B**, and **C** respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Imatinib

**(STI571; CGP-57148B)** Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



**Purity:** 99.54%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

## Imatinib D4

**(STI571 D4; CGP-57148B D4)** Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



**Purity:** ≥99.0%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Imatinib Mesylate

**(STI571 Mesylate; CGP-57148B Mesylate)** Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** ($IC_{50}$=100 nM) tyrosine kinases.



**Purity:** 99.91%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

## Imatinib-d8

**(STI571-d8; CGP-57148B-d8)** Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

## ISCK03

Cat. No.: HY-101443

ISCK03 is a specific **SCF/c-Kit** inhibitor.



Purity: 99.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an $IC_{50}$ of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with $IC_{50}$s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with $IC_{50}$s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

## Lenvatinib

**(E7080)** Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Lenvatinib mesylate

**(E7080 mesylate)** Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Lenvatinib-d4

**(E7080-d4)** Cat. No.: HY-10981S

Lenvatinib-d4 (E7080-d4) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## Lenvatinib-d5

**(E7080-d5)** Cat. No.: HY-10981S1

Lenvatinib-d5 (E7080-d5) is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

## Linifanib

**(ABT-869; AL-39324)** Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with $IC_{50}$s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## M4205

Cat. No.: HY-132166

M4205 is a **c-KIT** inhibitor, with an $IC_{50}$ of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17.



**Purity:** 99.47%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Masitinib

**(AB1010)**

Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** ($IC_{50}$=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** ($IC_{50}$s=540/800 nM), **Lyn** ($IC_{50}$= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



**Purity:** 99.98%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

## Masitinib mesylate

**(AB-1010 mesylate)**

Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** ($IC_{50}$=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** ($IC_{50}$s=540/800 nM), **Lyn** ($IC_{50}$= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



**Purity:** 99.76%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

## Motesanib

**(AMG 706)**

Cat. No.: HY-10228

Motesanib (AMG 706) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with $IC_{50}$< **/b>s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.**.



**Purity:** 99.99%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## Motesanib Diphosphate

**(AMG 706 Diphosphate)**

Cat. No.: HY-10229

Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with $IC_{50}$s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.



**Purity:** 99.85%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

## Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with $IC_{50}$s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



**Purity:** 98.13%
**Clinical Data:** Phase 1
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Pazopanib

**(GW786034)**

Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with $IC_{50}$s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



**Purity:** 99.77%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Pazopanib Hydrochloride

**(GW786034 (Hydrochloride))**

Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an $IC_{50}$ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



**Purity:** 99.84%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

## Pazopanib-d6

**(GW786034-d6)**

Cat. No.: HY-10208S

Pazopanib-d6 (GW786034-d6) is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with $IC_{50}$s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **$p210^{Bcr\text{-}Abl}$ kinase** inhibitor, with an **$IC_{50}$** of 5 nM for inhibiting the autophosphorylation of **$p210^{Bcr\text{-}Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with **$IC_{50}$**s of 0.8 nM and 50 nM, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 5 mg, 10 mg

## Pexidartinib

**(PLX-3397)**

Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with **$IC_{50}$**s of 20 and 10 nM, respectively.



**Purity:** 99.64%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

## Pexidartinib hydrochloride

**(PLX-3397 hydrochloride)**

Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with **$IC_{50}$**s of 20 and 10 nM, respectively.



**Purity:** 99.89%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg, 1 g

## PLX647

Cat. No.: HY-13838

PLX647 is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with **$IC_{50}$**s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR ($IC_{50}$s=91 and 130 nM, respectively).



**Purity:** 99.07%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with **$IC_{50}$**s of 28 and 16 nM, reapectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Ripretinib

**(DCC-2618)**

Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



**Purity:** 99.33%
**Clinical Data:** Launched
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

## Sitravatinib

**(MGCD516; MG-516)**

Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with **$IC_{50}$**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



**Purity:** 99.59%
**Clinical Data:** Phase 3
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

## Sitravatinib malate

**(MGCD516 malate; MG-516 malate)**

Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with **$IC_{50}$**s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



**Purity:** >98%
**Clinical Data:** Phase 3
**Size:** 1 mg, 5 mg

## SU11652

Cat. No.: HY-112452

SU11652 is a potent **receptor tyrosine kinase (RTK)** inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including **VEGFR**, **FGFR**, **PDGFR**, and **Kit**. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with **$IC_{50}$**s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



**Purity:** 98.90%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with **$IC_{50}$**s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



**Purity:** 99.95%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

## Tandutinib

**(MLN518; CT53518)**

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an **$IC_{50}$** of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with **$IC_{50}$**s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



**Purity:** 99.48%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 50 mg, 100 mg

## Tandutinib hydrochloride

**(MLN518 hydrochloride; CT53518 hydrochloride)**

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an **$IC_{50}$** of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with **$IC_{50}$**s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



**Purity:** 98.84%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 50 mg, 100 mg

## Telatinib

**(Bay 57-9352)**

Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with **$IC_{50}$**s of 6, 4, 15 and 1 nM, respectively.



**Purity:** 98.72%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Telatinib mesylate

**(Bay 57-9352 mesylate)**

Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with **$IC_{50}$**s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



**Purity:** 99.46%
**Clinical Data:** Phase 2
**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Toceranib

**(SU11654; PHA 291639E)**

Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with **$K_i$**s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



**Purity:** 96.25%
**Clinical Data:** Launched
**Size:** 10 mg, 50 mg

## Toceranib phosphate

**(SU11654 phosphate; PHA 291639E phosphate)**

Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with **$K_i$**s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



**Purity:** 98.02%
**Clinical Data:** Launched
**Size:** 10 mg, 25 mg, 50 mg, 100 mg

## Toceranib-d8

Cat. No.: HY-10330S

Toceranib-d8 (SU11654-d8) is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with **$K_i$**s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



**Purity:** >98%
**Clinical Data:**
**Size:** 1 mg, 10 mg

## Tyrphostin AG1296

**(AG1296)**

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an **$IC_{50}$** of 0.8 μM.



**Purity:** 99.25%
**Clinical Data:** No Development Reported
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with **$IC_{50}$**s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



**Purity:** >98%
**Clinical Data:** No Development Reported
**Size:** 1 mg, 5 mg

## Vimseltinib

**(DCC-3014)** Cat. No.: HY-136256

Vimseltinib (DCC-3014) is a **c-FMS** (**CSF-IR**) and **c-Kit** dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has $IC_{50}$s of <0.01 μM and 0.1-1 μM, respectively.



**Purity:** 99.08%
**Clinical Data:** Phase 2
**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg